REUTERS - Teva Pharmaceuticals is collaborating with Intel Corporation to develop a wearable device and machine-learning platform for Huntington disease patients, Teva said on Thursday.
The platform will monitor and analyze key symptoms that impact daily living to better understand disease progression and improve treatment evaluation, Teva, the world’s largest generic drug maker, said.
Huntington is a fatal neurodegenerative disease characterized by uncoordinated and uncontrollable movements, cognitive deterioration and behavioral and/or psychological problems.
As part of a joint study, patients will be asked to use a smartphone and wear a smartwatch equipped with sensing technology that continuously measures their functioning and movement. These data will be wirelessly streamed to a cloud-based platform developed by Intel to analyze data from wearable devices.
Proprietary algorithms will then translate these data, in near real-time, into objective scores of motor symptom severity. The study will start towards the end of the year and will take place in centers in the U.S. and Canada.
“Current measurement of symptoms is largely based on observation when the patient sees the doctor,” said Michael Hayden, president of Teva Global R&D. “This technology now provides us with an opportunity to have continuous monitoring.”
Want to enjoy 'Zen' reading - with no ads and just the article? Subscribe todaySubscribe now